{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T15:51:05Z","timestamp":1763308265238,"version":"3.41.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.7759\/cureus.85291","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:09:12Z","timestamp":1748963352000},"source":"Crossref","is-referenced-by-count":1,"title":["A Probable Case of Tirzepatide-Induced Acute Pancreatitis"],"prefix":"10.7759","author":[{"given":"Yovan","family":"Sumaruth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudramun","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris","family":"Chater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurav","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamzin","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref2","article-title":"Tirzepatide","author":"Farzam K","year":"2024","unstructured":"Farzam K, Patel P. Tirzepatide. StatPearls. StatPearls Publishing, Treasure Island, Florida; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14943","article-title":"Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS-1 to -5 studies","volume":"25","author":"Lingvay I","year":"2023","unstructured":"Lingvay I, Cheng AY, Levine JA, et al.. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS-1 to -5 studies. Diabetes Obes Metab. 2023, 25:965-74. 10.1111\/dom.14943","journal-title":"Diabetes Obes Metab"},{"key":"ref4","article-title":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury","year":"2019","unstructured":"Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2019."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng Q","year":"2023","unstructured":"Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023, 14:1214334. 10.3389\/fendo.2023.1214334","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai W","year":"2024","unstructured":"Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024, 12:1277113. 10.3389\/fpubh.2024.1277113","journal-title":"Front Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide\u00a01 receptor agonists","volume":"38","author":"Ard J","year":"2021","unstructured":"Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide\u00a01 receptor agonists. Adv Ther. 2021, 38:2821-39. 10.1007\/s12325-021-01710-0","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref10","article-title":"Summary of Product Characteristics: Mounjaro","year":"2024","unstructured":"Summary of Product Characteristics. Mounjaro. European Medicines Agency, Amsterdam, The Netherlands; 2024."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh S","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013, 173:534-9. 10.1001\/jamainternmed.2013.2720","journal-title":"JAMA Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials","volume":"103","author":"Monami M","year":"2014","unstructured":"Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diabetes Res Clin Pract. 2014, 103:269-75. 10.1016\/j.diabres.2014.01.010","journal-title":"Diabetes Res Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12386","article-title":"Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies","volume":"17","author":"Wang T","year":"2015","unstructured":"Wang T, Wang F, Gou Z, Tang H, Li C, Shi L, Zhai S. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015, 17:32-41. 10.1111\/dom.12386","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.4103\/1947-2714.104315","article-title":"Counselling patients for GLP-1 analogue therapy: comparing GLP-1 analogue with insulin counselling","volume":"4","author":"Kalra S","year":"2012","unstructured":"Kalra S, Kalra B. Counselling patients for GLP-1 analogue therapy: comparing GLP-1 analogue with insulin counselling. N Am J Med Sci. 2012, 4:638-40.","journal-title":"N Am J Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0822","article-title":"Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls","volume":"62","author":"Drucker DJ","year":"2013","unstructured":"Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013, 62:3316-23. 10.2337\/db13-0822","journal-title":"Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i3.252","article-title":"Pancreatitis-imaging approach","volume":"5","author":"Busireddy KK","year":"2014","unstructured":"Busireddy KK, AlObaidy M, Ramalho M, Kalubowila J, Baodong L, Santagostino I, Semelka RC. Pancreatitis-imaging approach. World J Gastrointest Pathophysiol. 2014, 5:252-70. 10.4291\/wjgp.v5.i3.252","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-011-0129-9","article-title":"Magnetic resonance cholangiopancreatography: the ABC of MRCP","volume":"3","author":"Griffin N","year":"2012","unstructured":"Griffin N, Charles-Edwards G, Grant LA. Magnetic resonance cholangiopancreatography: the ABC of MRCP. Insights Imaging. 2012, 3:11-21. 10.1007\/s13244-011-0129-9","journal-title":"Insights Imaging"},{"key":"ref18","unstructured":"National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity - a practical guide to using medicines to manage overweight and obesity. (2024). Accessed: August 26, 2024: https:\/\/www.nice.org.uk\/guidance\/ta1026\/resources\/a-practical-guide-to-using-medicines-to-manage-overweight-and-obesi...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/366761-a-probable-case-of-tirzepatide-induced-acute-pancreatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:09:22Z","timestamp":1748963362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/366761-a-probable-case-of-tirzepatide-induced-acute-pancreatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.85291","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}